Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01565772 · ClinicalTrials.gov registry record · Phase 1

Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer

A Phase 1 study, sponsored by Massachusetts General Hospital.

Terminated
Registry status
Phase 1
Development phase
4
Enrollment target

NCT01565772: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.

NCT01565772 is a Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01565772, a Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.

TERMINATED
Registry status
Phase 1
Development phase
4 participants
Enrollment target

Study Summary

This research study is looking at an alternative way of delivering radiation therapy with protons. Protons are tiny particles with a positive charge that can be controlled to travel a certain distance and stop inside the body. In theory, this allows better control of where the radiation dose is delivered as compared to photons. Information from other research studies suggests that proton radiation may help to reduce unwanted side effects from radiation and allow an increase in radiation dose that increase the odds of tumor killing. The purpose of this study is to determine the safest dose of proton radiation therapy to give in combination with standard chemotherapy in participants with Non-Small Cell Lung Cancer (NSCLC).

Primary Outcome

To establish the MTD of a proton beam-based regimen consisting of 25 fractions, together with concurrent standard cisplatin and etoposide chemotherapy followed by surgery +/- adjuvant chemotherapy for Stage III NSCLC, and to describe post-treatment surgical complications and treatment toxicity using CTCAE v4.0

Interventions

  • DRUG Cisplatin
  • DRUG Etoposide
  • RADIATION Proton Beam Radiation

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2012-03
Est. Completion 2015-06
Phase Phase 1
Massachusetts General Hospital

2,032 total trials

Why NCT01565772 stopped before completion

NCT01565772 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.

NCT01565772 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01565772 about?

NCT01565772 is a clinical study titled "Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer". This research study is looking at an alternative way of delivering radiation therapy with protons. Protons are tiny particles with a positive charge that can be controlled to travel a certain distance and stop inside the body. In theory, this allows better control of where the radiation dose is deli...

What is the current status of trial NCT01565772?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2012-03. Estimated completion is 2015-06.

What interventions are being tested in trial NCT01565772?

The interventions under investigation include: Cisplatin (DRUG), Etoposide (DRUG), Proton Beam Radiation (RADIATION).

Who is sponsoring clinical trial NCT01565772?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01565772's enrollment target sits among peer trials

4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01565772, the US trial registry maintained by the National Library of Medicine. NCT01565772 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.